OBJECTIVE: It is unclear whether the ability to respond to vaccines is restored by antiretroviral therapy. We evaluated the influenza-specific immune responses elicited by a virosomal vaccine in HIV-infected children on long-term successful highly active antiretroviral therapy (HAART). METHODS: This was an observational, prospective, open-label study enrolling 24 HIV-infected, HAART-treated (85 months' mean exposure), vaccine-naive children (median age=11.9 years) and 14 age- and gender-matched healthy controls. Mean CD4 T-cell counts (>900 cells/microL) and percentages (>37%) were comparable. The HIV RNA level was <50 copies/mL in all patients. Children received a single dose of trivalent virosome-adjuvanted influenza vaccine. A/H3N2-, A/H1N1-, and B-antigen-specific antibody (Ab) titers and subclasses and vaccine-specific interferon-gamma (IFNgamma)- and interleukin (IL)-2-producing T lymphocytes were analyzed at baseline and 1 and 6 months after immunization. RESULTS: Seroconversion (>or=4-fold Ab titer raise in >40% of patients) and seroprotection (Ab titer>or=1:40 in >70% of patients) was achieved at 1 month in both groups; however, fewer HIV-infected children fulfilled these criteria. The A/H3N2- and A/H1N1-specific Ab geometric mean titers were lower in HIV-infected children compared with healthy controls at 1 and 6 months; interestingly, a boost in vaccine-specific IgG3 T helper 1 type Ab was seen in healthy controls alone. Finally, vaccine specific-IFNgamma- and IL-2-producing T lymphocytes were reduced at both time points in HIV-infected children compared with healthy controls. CONCLUSIONS: One injection of virosomal-adjuvanted influenza vaccine stimulates good immune responses, although the humoral and cellular immune responses are reduced in HIV-infected children compared to healthy children. This indicates that immunologic function impairments may persist upon HIV infection even if HIV-positive viremia is suppressed and immune recovery seems to be achieved.
OBJECTIVE: It is unclear whether the ability to respond to vaccines is restored by antiretroviral therapy. We evaluated the influenza-specific immune responses elicited by a virosomal vaccine in HIV-infectedchildren on long-term successful highly active antiretroviral therapy (HAART). METHODS: This was an observational, prospective, open-label study enrolling 24 HIV-infected, HAART-treated (85 months' mean exposure), vaccine-naive children (median age=11.9 years) and 14 age- and gender-matched healthy controls. Mean CD4 T-cell counts (>900 cells/microL) and percentages (>37%) were comparable. The HIV RNA level was <50 copies/mL in all patients. Children received a single dose of trivalent virosome-adjuvanted influenza vaccine. A/H3N2-, A/H1N1-, and B-antigen-specific antibody (Ab) titers and subclasses and vaccine-specific interferon-gamma (IFNgamma)- and interleukin (IL)-2-producing T lymphocytes were analyzed at baseline and 1 and 6 months after immunization. RESULTS: Seroconversion (>or=4-fold Ab titer raise in >40% of patients) and seroprotection (Ab titer>or=1:40 in >70% of patients) was achieved at 1 month in both groups; however, fewer HIV-infectedchildren fulfilled these criteria. The A/H3N2- and A/H1N1-specific Ab geometric mean titers were lower in HIV-infectedchildren compared with healthy controls at 1 and 6 months; interestingly, a boost in vaccine-specific IgG3 T helper 1 type Ab was seen in healthy controls alone. Finally, vaccine specific-IFNgamma- and IL-2-producing T lymphocytes were reduced at both time points in HIV-infectedchildren compared with healthy controls. CONCLUSIONS: One injection of virosomal-adjuvanted influenza vaccine stimulates good immune responses, although the humoral and cellular immune responses are reduced in HIV-infectedchildren compared to healthy children. This indicates that immunologic function impairments may persist upon HIV infection even if HIV-positive viremia is suppressed and immune recovery seems to be achieved.
Authors: Anne B Kristensen; William N Lay; Fernanda Ana-Sosa-Batiz; Hillary A Vanderven; Vijaya Madhavi; Karen L Laurie; Louise Carolan; Bruce D Wines; Mark Hogarth; Adam K Wheatley; Stephen J Kent Journal: J Virol Date: 2016-05-27 Impact factor: 5.103
Authors: N F Crum-Cianflone; G Collins; G Defang; E Iverson; L E Eberly; C Duplessis; J Maguire; A Ganesan; B K Agan; T Lalani; T Whitman; C Brandt; D Faix; P J Blair; T Burgess Journal: Clin Exp Immunol Date: 2012-04 Impact factor: 4.330
Authors: Joyce L Sanchez; Peter W Hunt; Cavan S Reilly; Hiroyu Hatano; Gregory J Beilman; Alexander Khoruts; Jake S Jasurda; Ma Somsouk; Ann Thorkelson; Samuel Russ; Jodi Anderson; Steven G Deeks; Timothy W Schacker Journal: J Infect Dis Date: 2014-10-24 Impact factor: 5.226
Authors: Sharat Srinivasula; Erin Gabriel; Insook Kim; Paula DeGrange; Alexis St Claire; Candace Mallow; Robert E Donahue; Chang Paik; H C Lane; Michele Di Mascio Journal: PLoS One Date: 2017-11-09 Impact factor: 3.240
Authors: Patricia M Flynn; Sharon Nachman; Petronella Muresan; Terence Fenton; Stephen A Spector; Coleen K Cunningham; Robert Pass; Ram Yogev; Sandra Burchett; Barbara Heckman; Anthony Bloom; L Jill Utech; Patricia Anthony; Elizabeth Petzold; Wende Levy; George K Siberry; Ruth Ebiasah; Judi Miller; Edward Handelsman; Adriana Weinberg Journal: J Infect Dis Date: 2012-05-21 Impact factor: 5.226
Authors: Robert F Pass; Sharon Nachman; Patricia M Flynn; Petronella Muresan; Terence Fenton; Coleen K Cunningham; William Borkowsky; James B McAuley; Stephen A Spector; Elizabeth Petzold; Wende Levy; George K Siberry; Ed Handelsman; L Jill Utech; Adriana Weinberg Journal: J Pediatric Infect Dis Soc Date: 2013-07-17 Impact factor: 3.164